Phosphagenics Signs License Agreement with Intas Pharmaceuticals

Melbourne drug delivery technology company Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) has signed a licensing agreement with Intas Pharmaceuticals Ltd, an India based pharmaceuticals company,  for the manufacture and sale of three anti-ageing products specifically formulated by Phosphagenics for the Indian market.

Under the terms of the agreement, Intas will pay an undisclosed royalty and will market the new products, incorporating Phosphagenics' patented TPM® technology, through dermatologists and general physicians in India. Intas officials said that the company will leverage its  substantial  existing pharmaceutical marketing and sales infrastructure that  covers  dermatologists and general physicians, to launch this new product line.

Phosphagenics CEO Dr Esra Ogru said the latest Intas agreement was another milestone in the company's commercial strategy to roll out its personal care products globally.

"Our cosmetic lines are gathering momentum internationally and this  latest agreement follows on from our arrangement  to sell products in the Asian region through the AS Watson and Company chain," she said.

Dr Ogru said India, with a population of over 1.2 billion people represented a largescale market opportunity for Phosphagenics.   It is expected  to launch  a full dermatological line of personal care products in India if the first three products are a success.

TPM® is a patented  topical and  transdermal  delivery technology which enables superior delivery of various active ingredients into or through the skin

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.